Abrostep M Tablet is a powerful respiratory formulation containing Acebrophylline (200 mg) and Montelukast (10 mg). This combination delivers a synergistic bronchodilator and anti-inflammatory effect, providing effective relief in asthma, bronchitis, and chronic obstructive pulmonary disease (COPD).
Acebrophylline, a xanthine derivative with mucolytic and bronchodilating properties, improves airway clearance, enhances oxygen flow, and reduces mucus viscosity. Montelukast, a selective leukotriene receptor antagonist, prevents airway inflammation and allergic bronchoconstriction, improving overall lung function and respiratory comfort.
This dual-action therapy ensures both symptomatic relief and long-term control, helping patients breathe easier while reducing dependency on acute inhaler use. It is widely prescribed by pulmonologists and general physicians for managing chronic airway disorders.
Belonging to the respiratory & pulmonology segment, Abrostep M Tablet is a high-potential B2B product for PCD pharma franchise, third-party manufacturing, and export channels. Its high clinical efficacy and recurring demand in both institutional and retail markets make it a profitable choice for pharma distributors across India.